Emmanuelle Charpentier and Jennifer Doudna  

Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in Chemistry 2020 for discovering one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors.

Using components of the CRISPR system, researchers can add, remove, or even alter specific DNA sequences. This technology has introduced new opportunities in cancer therapies, curing inherited diseases and also in plant inbreeding.

Also read: What is genome editing

Emmanuelle Charpentier who was studying a bacteria called Streptococcus pyogenes, noticed a previously unknown molecule called tracrRNA. Further studies revealed that this tracrRNA was part of the bacteria’s immune system and it helps the bacteria destroy viral DNA. She published this discovery in 2011.

The same year, along with Jennifer Doudnathey, she succeeded in recreating the bacteria’s scissors and reprogramming it. Charpentier and Doudna then proved that they can now use these scissors to cut any DNA molecule at a required site.

Nobel Prizes 2020

CRISPR is an abbreviation for clustered regularly interspaced short palindromic repeats.

These sequences are a part of the bacteria’s immune system. Bacteria that have survived a virus infection add a piece of the genetic code of the virus into its genome as a memory of the infection. In addition to these CRISPR sequences, researchers discovered special genes called CRISPR-associated, abbreviated as cas.

Also read: How safe is CRISPR

In 2018, a geneticist from China, He Jiankui claimed that he altered the genes of twin girls born this month to create the first gene-edited babies. He said that he used the CRISPR-Cas9 gene-editing technology to edit the genes of twin girls. The editing process, which he calls gene surgery, “worked safely as intended” and the girls are “as healthy as any other babies”, he said in a video.

Also read: Chinese court sentences 'gene-editing' scientist to three years in prison

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Start your 14 days free trial. Sign Up

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

Please enter a valid email address.

Subscribe to The Hindu now and get unlimited access.

Already have an account? Sign In

Start your 14 days free trial Sign Up

You can support quality journalism by turning off ad blocker or purchase a subscription for unlimited access to The Hindu.

Sign up for a 30 day free trial.